Business, markets and economy

Executives with the three European companies seeking to combine their space businesses say the merger is still needed.
SpaceNews · yesterday

Del-desiran was one of three clinical setbacks for Novartis within a week. On September 4, Novartis and Ionis Pharmaceut…
Genetic Engineering & Biotechnology News · —

Oracle had previously disclosed that Ellison planned to sell 50 million shares worth around $7.5 billion.
TechCrunch · 3 days ago

Insilico Medicine, an AI-based drug developer whose profile within biopharma has risen with its recent collaborations wi…
Genetic Engineering & Biotechnology News · —

Axiom Biosciences founder, CEO, and chairman Remo Moomiaie-Qajar, MD, tells GEN why his company intends to trade its fir…
Genetic Engineering & Biotechnology News · 4 days ago

Thanks to its windfall of revenue from tirzepatide, the pharma giant reported second-quarter revenue and other results t…
Genetic Engineering & Biotechnology News · 4 days ago

Revolution Medicines shares stayed relatively flat despite the FDA’s historic approval of the company’s oral pancreatic…
Genetic Engineering & Biotechnology News · 4 days ago
Equity indexes mixed ahead of central bank commentary
BBC News World · Jul 26, 2026

Investors and Palm fans are anxiously awaiting the unveiling of Palm's new product line in October. It's hoped that Palm…
Ars Technica · Sep 22, 2002

Ars Technica · Sep 13, 2002

Palm inc. is in trouble, and most everyone knows it. It can only be a sign of the times that Palm is considering a rever…
Ars Technica · Jul 28, 2002

If you were lucky enough to have bought some NVIDIA stock early last year (2001), perhaps you were also lucky enough to…
Ars Technica · Jul 23, 2002